Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial
8 affiliations
- 1Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
- 2Division of Medical Oncology, Istituto Nazionale Tumori IRCCS Regina Elena, Rome, Italy
- 3The Second Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, Hunan, China
- 4Department of Thoracic Surgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China
- 5Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China
- 6Department of Clinical Development, BeOne Medicines (Shanghai), Co., Ltd., Shanghai, China
- 7Department of Biostatistics/Clinical Development, BeOne Medicines (Beijing), Co., Ltd., Beijing, China
- 8Department of Patient-Reported Outcomes Function, Global Medical Affairs, BeOne Medicines USA, Inc., San Mateo, CA, USA
Abstract
Introduction: In the phase III RATIONALE-315 trial (NCT04379635), perioperative tislelizumab plus neoadjuvant chemotherapy significantly improved overall and event-free survival versus placebo plus chemotherapy in patients with resectable stage II–IIIA non–small cell lung cancer (NSCLC). Here, report prespecified patient-reported outcomes (PROs).
Methods: PROs were evaluated using the EORTC QLQ-C30 and QLQ-LC13 questionnaires. A mixed-effects model for repeated measures was used for PRO endpoints at neoadjuvant Cycle 3 and adjuvant Cycles 3, 5, and 7. Time to deterioration (TTD) was also analyzed.
Results: 453 patients were randomized to tislelizumab (n = 226) or placebo (n = 227). At adjuvant Cycles 3 and 5, chest pain was maintained with tislelizumab versus worsening with placebo (LSM difference −4.99 [95% CI: −9.06 to −0.93]; p = 0.016) and −4.15 [95% CI: −7.86 to −0.44]; p = 0.028, respectively). At adjuvant Cycle 7, greater improvement in coughing was observed in the tislelizumab arm versus placebo (−5.10 [95% CI: −9.79 to −0.40]; p = 0.034). TTD analysis showed a lower risk of chest pain with tislelizumab (HR 0.58; p = 0.004).
Conclusion: Perioperative tislelizumab improved coughing and chest pain compared with placebo in patients with resectable NSCLC. These data provide additional support of this regimen in this patient population.
Clinical trial registration: www.clinicaltrials.gov identifier is NCT04379635.
Related
- Adjuvant and Perioperative Systemic Therapy for Resectable Hepatocellular Carcinoma: Evidence, Biological Rationale, and Trial Design
- Immune checkpoint inhibitors across neoadjuvant, perioperative, and adjuvant settings for resectable non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials
- Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis
- Neoadjuvant Chemotherapy and Perioperative Complications Associated with Pulmonary Toxicity.
- Perioperative Safety, Surgical Morbidity, and Survival Outcomes of Neoadjuvant Chemotherapy (NACT-IDS) versus Primary Debulking Surgery (PDS) in Elderly Patients with Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis
BibTeX
@article{yue2026perioperative,
title = {{Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial}},
author = {Dongsheng Yue and Federico Cappuzzo and Wenxiang Wang and Hongxu Liu and Qixun Chen and Shengfei Wang and Shiang Jiin Leaw and Bin Yao and Frederick B. Barnes and Gisoo Barnes and Changli Wang},
journal = {Future Oncology},
year = {2026},
month = nov,
doi = {10.1080/14796694.2026.2743385},
url = {https://doi.org/10.1080/14796694.2026.2743385},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial
AU - Dongsheng Yue
AU - Federico Cappuzzo
AU - Wenxiang Wang
AU - Hongxu Liu
AU - Qixun Chen
AU - Shengfei Wang
AU - Shiang Jiin Leaw
AU - Bin Yao
AU - Frederick B. Barnes
AU - Gisoo Barnes
AU - Changli Wang
PY - 2026
DA - 2026/11/06
JO - Future Oncology
DO - 10.1080/14796694.2026.2743385
UR - https://doi.org/10.1080/14796694.2026.2743385
AB - Introduction: In the phase III RATIONALE-315 trial (NCT04379635), perioperative tislelizumab plus neoadjuvant chemotherapy significantly improved overall and event-free survival versus placebo plus chemotherapy in patients with resectable stage II–IIIA non–small cell lung cancer (NSCLC). Here, report prespecified patient-reported outcomes (PROs). Methods: PROs were evaluated using the EORTC QLQ-C30 and QLQ-LC13 questionnaires. A mixed-effects model for repeated measures was used for PRO endpoints at neoadjuvant Cycle 3 and adjuvant Cycles 3, 5, and 7. Time to deterioration (TTD) was also analyzed. Results: 453 patients were randomized to tislelizumab (n = 226) or placebo (n = 227). At adjuvant Cycles 3 and 5, chest pain was maintained with tislelizumab versus worsening with placebo (LSM difference −4.99 [95% CI: −9.06 to −0.93]; p = 0.016) and −4.15 [95% CI: −7.86 to −0.44]; p = 0.028, respectively). At adjuvant Cycle 7, greater improvement in coughing was observed in the tislelizumab arm versus placebo (−5.10 [95% CI: −9.79 to −0.40]; p = 0.034). TTD analysis showed a lower risk of chest pain with tislelizumab (HR 0.58; p = 0.004). Conclusion: Perioperative tislelizumab improved coughing and chest pain compared with placebo in patients with resectable NSCLC. These data provide additional support of this regimen in this patient population. Clinical trial registration: www.clinicaltrials.gov identifier is NCT04379635.
SN - 1479-6694
SN - 1744-8301
ER -